ATYR
aTyr Pharma·NASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATYR
Atyr Pharma, Inc.
A company that focused on researching the extracellular functionality and signaling pathways of tRNA synthetases
10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121
Develops therapies for fibrosis and inflammation.
ATyr Pharma, Inc., was incorporated in Delaware on September 8, 2005. The company is a clinical-stage biotechnology company focused on developing therapies for the treatment of fibrosis and inflammation based on tRNA synthetase biology. Its lead drug candidate, efzofitimod, is a novel immunomodulator that is being investigated for the treatment of interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung diseases.
Company Financials
EPS
ATYR has released its 2026 Q2 earnings. EPS was reported at -0.11, versus the expected -0.12, beating expectations. The chart below visualizes how ATYR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
